These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21474222)

  • 1. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 5. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
    Hakim Z; Kucukarslan S
    Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
    Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
    Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
    Davis C; Abraham J
    Sociol Health Illn; 2011 Jul; 33(5):731-47. PubMed ID: 21314687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
    Zierenberg O
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm.
    Contiades X; Golna C; Souliotis K
    Health Policy; 2007 Jun; 82(1):116-29. PubMed ID: 17049667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.